Cite
Iriyama N, Miura K, Hatta Y, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13(5):3803-3808doi: 10.3892/ol.2017.5920.
Iriyama, N., Miura, K., Hatta, Y., Kobayashi, S., Uchino, Y., Kurita, D., Sakagami, H., Takahashi, H., Sakagami, M., Kobayashi, Y., Nakagawa, M., Ohtake, S., Iizuka, Y., & Takei, M. (2017). Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncology letters, 13(5), 3803-3808. https://doi.org/10.3892/ol.2017.5920
Iriyama, Noriyoshi, et al. "Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib." Oncology letters vol. 13,5 (2017): 3803-3808. doi: https://doi.org/10.3892/ol.2017.5920
Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, Sakagami H, Takahashi H, Sakagami M, Kobayashi Y, Nakagawa M, Ohtake S, Iizuka Y, Takei M. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017 May;13(5):3803-3808. doi: 10.3892/ol.2017.5920. Epub 2017 Mar 27. PMID: 28521480; PMCID: PMC5431368.
Copy
Download .nbib